Reolysin (REOLYSIN®)

Description

Reolysin is an oncolytic virus therapy that utilizes a genetically unmodified reovirus to selectively target and destroy cancer cells. In colorectal cancer treatment, Reolysin is administered in combination with standard chemotherapy regimens including FOLFOX6 or FOLFIRI plus bevacizumab. The therapy shows particular promise in patients with KRAS-mutated metastatic colorectal cancer, as these mutations may enhance the virus's ability to replicate within cancer cells.

Mechanism of Action

Reolysin exploits defective antiviral responses in cancer cells, particularly those with activated Ras signaling pathways such as KRAS mutations. The reovirus preferentially replicates within malignant cells that have impaired interferon responses, leading to direct oncolysis and potential activation of anti-tumor immune responses. This selective replication causes cancer cell death while generally sparing normal cells with intact antiviral defenses.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials